Emergent Biosolutions
EBS
261 hedge funds and large institutions have $2.61B invested in Emergent Biosolutions in 2020 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 86 increasing their positions, 95 reducing their positions, and 20 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
145% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 20
11% more funds holding
Funds holding: 236 → 261 (+25)
7% more capital invested
Capital invested by funds: $2.43B → $2.61B (+$181M)
0.14% less ownership
Funds ownership: 87.12% → 86.98% (-0.14%)
9% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 95
37% less call options, than puts
Call options by funds: $1.49M | Put options by funds: $2.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
+$43.1M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$17.5M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$16.5M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$15.2M |
| 5 |
TFF
The Family Firm
Bethesda,
Maryland
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$19.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.7M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$16.2M |
| 4 |
BlackRock
New York
|
-$9.92M |
| 5 |
Lazard Asset Management
New York
|
-$9.47M |
EBS Hedge Fund Activity: Q1 2020 in Review
261 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2020, worth a combined $2.61B — up 7.4% from $2.43B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new EBS positions and 20 closed out — a net gain of 29 holders — while 86 added to existing stakes and 95 trimmed.
The largest buyer was EARNEST Partners, adding an estimated $43.1M. The largest seller was Rice Hall James & Associates, cutting an estimated $19.3M.
- 261 institutional investors held Emergent Biosolutions (EBS) as of Q1 2020, up from 236 in Q4 2019.
- Funds reported $2.61B of Emergent Biosolutions stock for Q1 2020, up 7.4% quarter-over-quarter.
- 49 funds opened new Emergent Biosolutions positions in Q1 2020 and 20 closed out, a net change of +29 holders.
- The largest Emergent Biosolutions buyer in Q1 2020 was EARNEST Partners, an estimated $43.1M added.
- The largest Emergent Biosolutions seller in Q1 2020 was Rice Hall James & Associates, an estimated $19.3M sold.
Based on aggregated 13F filings for Q1 2020.